Lipid Nanoparticle Manufacturing Market: Services & Technologies-Distribution by Type of Lipid Nanoparticle & Molecule Delivered, Company Size, Target Therapeutic Area, End-user, Key Geographical Regions: Industry Trends & Global Forecasts, 2023-2035

Description

The global lipid nanoparticle manufacturing market is valued at USD 0.66 billion in 2023 growing at a CAGR of 11.8% during the forecast period 2023-2035.

In recent years, the pharmaceutical industry has experienced significant expansion, evident in the increasing number of drugs undergoing approval or exploration in preclinical studies and clinical trials. However, a persistent hurdle in drug development lies in the poor water solubility and bioavailability of many compounds. Roughly 90% of drugs in development and nearly 40% of existing pharmacological products face challenges regarding solubility or permeability. These issues often lead to premature elimination from the body before they can be absorbed, impacting their effectiveness. Consequently, pharmaceutical firms are actively seeking solutions to overcome these obstacles. Among the various strategies to enhance the solubility and bioavailability of therapeutic agents, lipid nanoparticles (LNPs) and similar lipid-based additives have attracted substantial attention from drug developers. LNPs are recognized as a versatile platform in nanomedicine delivery due to their capacity to encapsulate diverse molecules and offer controlled drug release. As research in this field flourishes, the intellectual capital concerning the use of LNPs in drug delivery has also expanded.

Yet, manufacturing lipid nanoparticles is a complex and cost-intensive process that demands diverse expertise. Thus, pharmaceutical companies increasingly rely on specialized contract manufacturing organizations (CMOs) equipped with the necessary technology and know-how to tackle technical and operational challenges. Outsourcing to such service providers allows sponsors to tap into innovative LNP technologies and gain operational flexibility. Given the inherent advantages of LNPs-small size, multifunctional properties, and customizable surfaces-the market for LNP-based therapeutics is poised for significant growth in the foreseeable future. This growth will consequently drive expansion in the lipid nanoparticle manufacturing market during the projected period.

Key Market Segments:

Type of Lipid Nanoparticle

Solid Lipid Nanoparticles
Nanostructured Lipid Carriers

Type of Molecule Delivered

Nucleic Acids
Small Molecules
Peptides/ Proteins
Others

Company Size

Very Large and Large
Mid-sized
Small

Therapeutic Area

Infectious Diseases
Oncological Disorders
Blood Disorders
Rare Diseases
Other Disorders

Type of End User

Pharmaceutical and Biotechnology Companies
Academic and Research Institutes
Other End-users

Key Geographical Regions:

North America
Europe
Asia-Pacific
Rest of the World

Research Coverage:

The report studies the lipid nanoparticle manufacturing market based on type of lipid nanoparticle, type of molecule delivered, company size, target therapeutic area, type of end-user and key geographical regions
The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth
The report assesses the potential advantages and obstacles within the market for those involved and offers information on the competitive environment for top players in the market.
The report forecasts the revenue of market segments with respect to four major regions
Comprehensive methodology adopted for the study, encompassing assumptions, methodologies, and quality control measures for accuracy and reliability of findings.
Historical trends, currency fluctuations, foreign exchange impact, recession, and inflation measurements shaping the lipid nanoparticle manufacturing market.
High-level overview capturing current state and potential evolution of the lipid nanoparticle manufacturing market in the medium to long term.
Exploration of lipids, their types, advantages, applications in pharmaceuticals, challenges in formulation, and the rising need for outsourcing manufacturing operations.
Evaluation based on establishment year, company size, headquarters location, manufacturing facility location, operational scale, delivered molecule types, therapeutic areas, and additional services offered.
Evaluation based on formulation methods, molecule types, compatible dosage forms, administration routes, therapeutic areas, establishment year, company size, headquarters location, business models, and active players.
Examination based on establishment year, company size, headquarters location, manufacturing facilities, operational scale, lipid types, product types, additional services offered, and competitiveness analysis.
Comparative assessment of lipid nanoparticle contract manufacturing organizations based on company strength, service strength, and the number of manufacturing facilities.
Insightful analysis based on developer strength, technology aspects, and applicability in therapeutic areas.
Detailed profiles of key players in LNP manufacturing services and technology, featuring company overview, portfolios, recent developments, and future outlook.
Examination of partnerships between stakeholders since 2019, based on various parameters and regional distribution of involved companies.
Evaluation of mRNA vaccine and therapeutics developers for potential partnerships with lipid nanoparticle manufacturers, considering multiple criteria.
Detailed exploration of factors influencing the decision of companies to outsource LNP manufacturing or develop in-house capabilities.
Analysis of global installed capacity among LNP contract manufacturers based on company size, operational scale, and geographical distribution.
Identification and analysis of key drivers, potential restraints, emerging opportunities, and existing challenges impacting lipid nanoparticle manufacturing market growth.

Key Benefits of Buying this Report:

The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
The report provides stakeholders with a pulse on the lipid nanoparticle manufacturing market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Key Market Companies:

Acuitas Therapeutics
Ascendia Pharmaceuticals
Avanti Polar Lipids
BIOVECTRA
CordenPharma
Creative Biolabs
Curapath
Curia
Emergent Biosolutions
EUROAPI
Evonik

Formumax Scientific
Fresinius Kabi
Fujifilm
Integrated Nanotherapeutics
leon-nanodrugs
Matinas BioPharma
Merck
Pantherna Therapeutics
Precision NanoSystems
TLC Biosciences

Product Code: RA100461

1. PREFACE

1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Inclusions and Exclusions
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
- 2.7.1. Demographics
- 2.7.2. Economic Factors
- 2.7.3. Government Regulations
- 2.7.4. Supply Chain
- 2.7.5. COVID Impact / Related Factors
- 2.7.6. Market Access
- 2.7.7. Healthcare Policies
- 2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

3.1. Chapter Overview
3.2. Market Dynamics
- 3.2.1. Time Period
  - 3.2.1.1. Historical Trends
  - 3.2.1.2. Current and Forecasted Estimates
- 3.2.2. Currency Coverage
  - 3.2.2.1. Overview of Major Currencies Affecting the Market
  - 3.2.2.2. Impact of Currency Fluctuations on the Industry
- 3.2.3. Foreign Exchange Impact
  - 3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
  - 3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
- 3.2.4. Recession
  - 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
  - 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
- 3.2.5. Inflation
  - 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
  - 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

5.1. Chapter Overview
5.2. Overview of Lipids
5.3 Introduction to Lipid Nanoparticles
- 5.3.1. Types of Lipid Nanoparticles
  - 5.3.1.1. Solid Lipid Nanoparticles
  - 5.3.1.2. Nanostructured Lipid Carriers
- 5.3.2. Advantages of Lipid Nanoparticles
- 5.3.3. Applications of Lipid Nanoparticles in Pharmaceutical Industry
  - 5.3.3.1. Cancer Treatment
  - 5.3.3.2. Gene Therapy
  - 5.3.3.3. Vaccine Development
  - 5.3.3.4. Medical Imaging / Diagnostics
  - 5.3.3.5. Additional Applications
5.4. Challenges Associated with Lipid Nanoparticle Manufacturing
5.5. Need for Outsourcing Lipid Nanoparticle Manufacturing
5.6. Concluding Remarks

6. LIPID NANOPARTICLES: SERVICE PROVIDERS LANDSCAPE

6.1. Chapter Overview
6.2. Lipid Nanoparticle Manufacturing: List of Service Providers
- 6.2.1 Analysis by Year of Establishment
- 6.2.2 Analysis by Company Size
- 6.2.3 Analysis by Location of Headquarters
- 6.2.4 Analysis by Company Size and Location of Headquarters
- 6.2.5 Analysis by Location of Lipid Nanoparticle Manufacturing Facility
- 6.2.6 Analysis by Scale of Operation
- 6.2.7 Analysis by Type of Molecule Delivered
- 6.2.8 Analysis by Therapeutic Area
- 6.2.9 Analysis by Type of Additional Services Offered

7. LIPID NANOPARTICLES: TECHNOLOGY LANDSCAPE

7.1. Chapter Overview
7.2. Lipid Nanoparticle: Technology Landscape
- 7.2.1. Analysis by Type of Formulation Method
- 7.2.2. Analysis by Type of Molecule Delivered
- 7.2.3. Analysis by Compatible Dosage Form
- 7.2.4. Analysis by Routes of Administration
- 7.2.5. Analysis by Therapeutic Area
7.3. Lipid Nanoparticle Technologies: List of Technology Developers
- 7.3.1. Analysis by Year of Establishment
- 7.3.2. Analysis by Company Size
- 7.3.3. Analysis by Location of Headquarters
- 7.3.4. Analysis by Company Size and Location of Headquarters
- 7.3.5. Analysis by Business Model
- 7.3.6. Most Active Players: Analysis by Number of Technologies

8. OTHER TYPES OF LIPIDS: SERVICE PROVIDERS LANDSCAPE

8.1. Chapter Overview
8.2. Other Types of Lipids: List of Service Providers
- 8.2.1 Analysis by Year of Establishment
- 8.2.2 Analysis by Company Size
- 8.2.3 Analysis by Location of Headquarters
- 8.2.4 Analysis by Company Size and Location of Headquarters
- 8.2.5. Analysis by Location of Manufacturing Facility
- 8.2.6. Analysis by Scale of Operation
- 8.2.7 Analysis by Type of Lipid Manufactured
- 8.2.8. Analysis by Scale of Operation and Type of Lipid Manufactured
- 8.2.9. Analysis by Type of Product
- 8.2.10. Analysis by Type of Additional Services Offered
- 8.2.11. Analysis by Type of Product and Type of Additional Services Offered

9. COMPANY COMPETITIVENESS ANALYSIS

9.1. Chapter Overview
9.2. Assumptions and Key Parameters
9.3. Methodology
9.4. Lipid Nanoparticle Manufacturing Service Providers: Company Competitiveness Analysis
- 9.4.1. Company Competitiveness Analysis: Small Players
- 9.4.2. Company Competitiveness Analysis : Mid-sized Players
- 9.4.3. Company Competitiveness Analysis : Large and Very Large Players

10. TECHNOLOGY COMPETITIVENESS ANALYSIS

10.1. Chapter Overview
10.2. Assumptions and Key Parameters
10.3. Methodology
10.4. Lipid Nanoparticle Technologies: Competitiveness Analysis
- 10.4.1. Technology Competitiveness Analysis: Players based in North America
- 10.4.2. Technology Competitiveness Analysis: Players based in Europe and Asia-Pacific

11. COMPANY PROFILES: SERVICE PROVIDERS OF LIPID NANOPARTICLES

11.1. Chapter Overview
11.2. Curia
- 11.2.1. Company Overview
- 11.2.2. Service Portfolio
- 11.2.3. Recent Developments and Future Outlook
11.3. Emergent BioSolutions
- 11.3.1. Company Overview
- 11.3.2. Service Portfolio
- 11.3.3. Recent Developments and Future Outlook
11.4. EUROAPI
- 11.4.1. Company Overview
- 11.4.2. Service Portfolio
- 11.4.3. Recent Developments and Future Outlook
11.5. Evonik
- 11.5.1. Company Overview
- 11.5.2. Service Portfolio
- 11.5.3. Recent Developments and Future Outlook
11.6. Ardena
- 11.6.1. Company Overview
- 11.6.2. Service Portfolio
11.7. BIOVECTRA
117.1. Company Overview
- 11.7.2. Service Portfolio
11.8. Precision NanoSystems
- 11.8.1. Company Overview
- 11.8.2. Service Portfolio

12. COMPANY PROFILES: LIPID NANOPARTICLE TECHNOLOGY DEVELOPERS

12.1. Chapter Overview
12.2. Ascendia Pharmaceuticals
- 12.2.1. Company Overview
- 12.2.2. Lipid Nanoparticle Technology Portfolio
- 12.2.3. Recent Developments and Future Outlook
12.3. leon-nanodrugs
- 12.3.1. Company Overview
- 12.3.2. Lipid Nanoparticle Technology Portfolio
- 12.3.3. Recent Developments and Future Outlook
12.4. Pantherna Therapeutics
- 12.4.1. Company Overview
- 12.4.2. Lipid Nanoparticle Technology Portfolio
- 12.4.3. Recent Developments and Future Outlook
12.5. TLC Biosciences
- 12.5.1. Company Overview
- 12.5.2. Lipid Nanoparticle Technology Portfolio
- 12.5.3. Recent Developments and Future Outlook
12.6. Acuitas Therapeutics
- 12.6.1. Company Overview
- 12.6.2. Service Portfolio
12.7. Integrated Nanotherapeutics
- 12.7.1. Company Overview
- 12.7.2. Service Portfolio
12.8. Matinas BioPharma
- 12.8.1. Company Overview
- 12.8.2. Service Portfolio

13. COMPANY PROFILES: SERVICE PROVIDERS OF OTHER TYPES OF LIPIDS

13.1. Chapter Overview
13.2. Avanti Polar Lipids
- 13.2.1. Company Overview
- 13.2.2. Service Portfolio
- 13.2.3. Recent Developments and Future Outlook
13.3. Corden Pharma
- 13.3.1. Company Overview
- 13.3.2. Service Portfolio
- 13.3.3. Recent Developments and Future Outlook
13.4. Fujifilm
- 13.4.1. Company Overview
- 13.4.2. Service Portfolio
- 13.4.3. Recent Developments and Future Outlook
13.5. Merck
- 13.5.1. Company Overview
- 13.5.2. Service Portfolio
- 13.5.3. Recent Developments and Future Outlook
13.6. FormuMax Scientific
- 13.6.1. Company Overview
- 12.6.2. Service Portfolio
13.7. Creative Biolabs
- 13.7.1. Company Overview
- 13.7.2. Service Portfolio
13.8. Fresenius Kabi
- 13.8.1. Company Overview
- 13.8.2. Service Portfolio

14. PARTNERSHIPS AND COLLABORATIONS

14.1. Chapter Overview
14.2. Partnership Models
14.3. Lipid Nanoparticles Services and Technologies: List of Partnerships and Collaborations
- 14.3.1. Analysis by Year of Partnership
- 14.3.2. Analysis by Type of Partnership
- 14.3.3. Analysis by Year and Type of Partnership
- 14.3.4. Analysis by Type of Molecule
- 14.3.5. Analysis by Therapeutic Area
- 14.3.6. Analysis by Type of Partner
- 14.3.7. Most Active Players: Analysis by Number of Partnerships
- 14.3.8. Analysis by Geography
  - 14.3.8.1. Intracontinental and Intercontinental Deals
  - 14.3.8.2. International and Local Deals

15. LIKELY PARTNER ANALYSIS

15.1. Chapter Overview
15.2. Methodology
15.2. mRNA Drug Developers: Potential Strategic Partners in North America
15.3. mRNA Drug Developers: Potential Strategic Partners in Europe and Asia-Pacific

16. MAKE VERSUS BUY DECISION FRAMEWORK

16.1. Chapter Overview
16.2. Assumptions and Key Parameters
16.3. Lipid Nanoparticle Service Providers: Make versus Buy Decision Making Framework
- 16.3.1. Scenario 1
- 16.3.2. Scenario 2
- 16.3.3. Scenario 3
- 16.3.4. Scenario 4
16.4. Concluding Remarks

17. CAPACITY ANALYSIS

17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Global Installed Lipid Nanoparticle Contract Manufacturing Capacity
- 17.3.1. Analysis by Range of Installed Capacity
- 17.3.2. Analysis by Company Size
- 17.3.3. Analysis by Scale of Operation
- 17.3.4. Analysis by Location of Manufacturing Facility
  - 17.3.4.1. Analysis of Installed Lipid Nanoparticle Contract Manufacturing Capacity in North America
  - 17.3.4.2. Analysis of Installed Lipid Nanoparticle Contract Manufacturing Capacity in Europe
  - 17.3.4.3. Analysis of Installed Lipid Nanoparticle Contract Manufacturing Capacity in Asia-Pacific
- 17.3.5. Concluding Remarks

18. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

18.1. Chapter Overview
18.2. Market Drivers
18.3. Market Restraints
18.4. Market Opportunities
18.5. Market Challenges
18.6. Conclusion

19. GLOBAL LIPID NANOPARTICLE MANUFACTURING MARKET

19.1. Chapter Overview
19.2. Assumptions and Methodology
19.3. Global Lipid Nanoparticle Manufacturing Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
- 19.3.1. Scenario Analysis
  - 19.3.1.1. Conservative Scenario
  - 19.3.1.2. Optimistic Scenario
19.4. Key Market Segmentations

20. LIPID NANOPARTICLE MANUFACTURING MARKET, BY TYPE OF LIPID NANOPARTICLE

20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Lipid Nanoparticle Manufacturing Market: Distribution by Type of Lipid Nanoparticle, 2028, 2023 and 2035
- 20.3.1. Solid Lipid Nanoparticles, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
- 20.3.2. Nanostructured Lipid Carriers, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
20.7. Data Triangulation and Validation

21. LIPID NANOPARTICLE MANUFACTURING MARKET, BY TYPE OF MOLECULE DELIVERED

21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Lipid Nanoparticle Manufacturing Market: Distribution by Type of Molecule Delivered, 2018, 2023 and 2035
- 21.3.1. Nucleic Acids, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
- 21.3.2. Small Molecules, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
- 21.3.3. Peptides / Proteins, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
- 21.3.4. Other Molecules, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
21.4. Data Triangulation and Validation

22. LIPID NANOPARTICLE MANUFACTURING MARKET, BY COMPANY SIZE

22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Lipid Nanoparticle Manufacturing Market: Distribution by Company Size, 2018, 2023 and 2035
- 22.3.1. Very Large and Large Companies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
- 22.3.2. Mid-sized Companies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
- 22.3.3. Small Companies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
22.4. Data Triangulation and Validation

23. LIPID NANOPARTICLE MANUFACTURING MARKET, BY TARGET THERAPEUTIC AREA

23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. Lipid Nanoparticle Manufacturing Market: Distribution by Target Therapeutic Area, 2018, 2023 and 2035
- 23.3.1. Infectious Diseases, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
- 23.3.2. Oncological Disorders, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
- 23.3.3. Blood Disorders, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
- 23.3.4. Rare Diseases, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
- 23.3.5. Other Disorders, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
23.4. Data Triangulation and Validation

24. LIPID NANOPARTICLE MANUFACTURING MARKET, BY TYPE OF END-USER

24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. Lipid Nanoparticle Manufacturing Market: Distribution by Type of End-user, 2018, 2023 and 2035
- 24.3.1. Pharmaceutical and Biotechnology Companies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
- 24.3.2. Academic and Research Institutes, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
- 24.3.3. Other End-Users: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
24.4. Data Triangulation and Validation

25. LIPID NANOPARTICLE MANUFACTURING MARKET, BY KEY GEOGRAPHICAL REGIONS

25.1. Chapter Overview
25.2. Key Assumptions and Methodology
25.3. Lipid Nanoparticle Manufacturing Market: Distribution by Key Geographical Regions, 2018, 2023 and 2035
- 25.3.1. North America, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
- 25.3.2. Europe, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
- 25.3.3. Asia-Pacific, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
- 25.3.4. Rest of the World, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
25.4. Data Triangulation and Validation